Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prediction of short- and long-term mortality in takotsubo syndrome: the InterTAK Prognostic Score.

European journal of heart failure·2019

Same author

Leptin in Human Milk and Child Body Mass Index: Results of the Ulm Birth Cohort Studies.

Nutrients·2019

Same author

The Associations of Diuretics and Laxatives Use with Cardiovascular Mortality. An Individual Patient-Data Meta-analysis of Two Large Cohort Studies.

Cardiovascular drugs and therapy·2019

Same author

Clinical Features and Outcomes of Patients With Malignancy and Takotsubo Syndrome: Observations From the International Takotsubo Registry.

Journal of the American Heart Association·2019

Same author

Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients.

European heart journal·2019

Same author

Repeat Measurements of High Sensitivity Troponins for the Prediction of Recurrent Cardiovascular Events in Patients With Established Coronary Heart Disease: An Analysis From the KAROLA Study.

Journal of the American Heart Association·2019

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

Integrating biomarkers: the new frontier?

Wolfgang Koenig¹

¹Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, Ulm, Germany. wolfgang.koenig@uniklinik-ulm.de

Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum

|June 3, 2010

Summary

Improving cardiovascular disease (CVD) risk prediction requires new biomarkers. Inflammatory markers and subclinical disease indicators show promise but need further validation for clinical use.

Area of Science:

Cardiovascular Medicine
Biomarker Discovery
Atherosclerosis Research

Background:

Current cardiovascular disease (CVD) risk scores have limitations in accurately stratifying patient risk.
Atherosclerosis involves complex pathophysiological pathways, including inflammation, necessitating novel biomarkers.
Circulating inflammatory biomarkers and markers of subclinical disease are being investigated to enhance CVD risk assessment.

Purpose of the Study:

To explore the potential of additional biomarkers, including inflammatory markers and indicators of subclinical disease, to improve cardiovascular disease (CVD) risk stratification.
To evaluate the role of systemic inflammatory biomarkers and non-invasive imaging techniques in predicting future CVD events.
To assess the need for further research, including integrated approaches and omics technologies, to establish clinical utility.

Related Experiment Videos

Last Updated: Jun 12, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

Main Methods:

Review of existing literature on blood biomarkers (inflammatory, genetic) and imaging techniques (carotid intima-media thickness, coronary calcium) for CVD risk.
Analysis of the association between elevated circulating inflammatory biomarker concentrations and future CVD events.
Consideration of non-invasive imaging techniques for predicting CVD risk.

Main Results:

Elevated concentrations of circulating inflammatory biomarkers are associated with future cardiovascular disease (CVD) events.
Non-invasive imaging techniques like carotid intima-media thickness and coronary calcium scoring show predictive value for CVD.
The clinical utility of most individual biomarkers and integrated approaches remains to be firmly established.

Conclusions:

Additional biomarkers, particularly inflammatory markers and indicators of subclinical disease, are needed to improve cardiovascular disease (CVD) risk stratification beyond current scores.
While promising, further research and validation, especially through serial measurements in large populations and integration of omics data, are required to establish the clinical usefulness of these novel markers and integrated strategies.